



The Illinois Medical Bulletin



The Role of Pharmacological Thromboprophylaxis in Preventing Venous Thromboembolism in Acutely Ill Medical Patients: A Review of Landmark Trial Evidence

¹A. Bondy, ²A. Borah

^{1,2} University of Illinois College of Medicine

Corresponding Email : drbondy28743@gmail.com

Article History :

Received date : 2013/10/12
Revised date : 2013/11/28
Accepted date : 2013/12/09
Published date : 2014/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Hospitalized, acutely ill medical patients face a significant risk of venous thromboembolism (VTE), a major cause of preventable hospital-acquired morbidity and mortality. For many years, the routine use of pharmacological prophylaxis in this broad and heterogeneous population was not a universal standard of care, owing to a lack of definitive evidence.

Literature Review: A review of pivotal literature reveals a series of large-scale, randomized, placebo-controlled trials that decisively established the benefit of thromboprophylaxis. Landmark studies such as the PREVENT trial demonstrated that prophylactic doses of low-molecular-weight heparin (LMWH) significantly reduced the incidence of VTE, including proximal deep vein thrombosis and pulmonary embolism, compared to placebo. The ARTEMIS trial subsequently confirmed this benefit using the synthetic Factor Xa inhibitor, fondaparinux. This substantial reduction in thrombotic events was achieved with an acceptable safety profile, without a significant increase in major bleeding complications. This body of high-quality evidence prompted the development of risk assessment models and the widespread adoption of

routine VTE prophylaxis for at-risk medical patients into major international clinical practice guidelines.

Conclusion: The evidence reviewed established pharmacological thromboprophylaxis as a safe, effective, and essential intervention for at-risk medical inpatients. This research transformed the standard of care, making VTE prevention a fundamental component of patient safety and hospital quality improvement initiatives worldwide.

Keywords: Venous Thromboembolism (VTE), Thromboprophylaxis, Deep Vein Thrombosis (DVT), Low-Molecular-Weight Heparin (LMWH), Hospitalized Medical Patients.

INTRODUCTION

Venous thromboembolism (VTE), a condition that encompasses both deep vein thrombosis (DVT) and its life-threatening complication, pulmonary embolism (PE), is a leading cause of preventable death among hospitalized patients. The prothrombotic state induced by acute medical illness, combined with patient immobility, creates a high-risk environment for the development of VTE. While the benefits of thromboprophylaxis were well-established for high-risk surgical patients, its role in the large and diverse population of patients hospitalized for acute medical conditions—such as severe heart failure, respiratory failure, acute infectious diseases, or inflammatory disorders—was historically less certain.

The challenge lay in balancing the potential benefit of preventing VTE against the potential harm of causing bleeding with anticoagulant medications. A clear need existed for high-quality evidence from large, randomized controlled trials to define the risk-benefit ratio and to guide clinical practice for this ubiquitous patient group. This literature review will synthesise the pivotal clinical trial evidence that established the efficacy and safety of pharmacological thromboprophylaxis as a standard of care for acutely ill medical patients.

LITERATURE REVIEW

The establishment of routine thromboprophylaxis for medical inpatients was driven by a series of landmark clinical trials that provided clear and consistent evidence of benefit.

Foundational trials compared the efficacy of low-molecular-weight heparins (LMWHs) against placebo. The MEDENOX trial was a seminal study that demonstrated a significant reduction in VTE risk with enoxaparin. Building on this, the PREVENT trial was another large,

randomized, placebo-controlled study that evaluated the LMWH dalteparin in acutely ill medical patients. The study found a statistically significant reduction in the primary endpoint of VTE, driven by a decrease in both symptomatic and asymptomatic events detected by routine ultrasound. The benefit was clear and confirmed the efficacy of the LMWH class in this setting (Leizorovicz et al., 2004). Systematic reviews and meta-analyses combining the data from these and other trials further strengthened this conclusion, showing a consistent and robust risk reduction for VTE with LMWH prophylaxis (Alikhan et al., 2003).

The evidence base was further expanded by the investigation of newer anticoagulant agents. The ARTEMIS trial was a major international, randomized study that compared the selective Factor Xa inhibitor, fondaparinux, with placebo in a similar population of acutely ill medical patients with restricted mobility. The results were concordant with the LMWH trials, showing that fondaparinux significantly reduced the rate of VTE by approximately half compared to placebo. This trial confirmed that the benefit was a class effect of anticoagulation and provided another effective agent for prophylaxis (Cohen et al., 2006).

A crucial aspect of these trials was the assessment of safety. While any anticoagulant carries a risk of bleeding, these large studies consistently demonstrated that the rates of major bleeding in the groups receiving pharmacological prophylaxis were not significantly different from the rates in the placebo groups. This finding was critical, as it established a favorable risk-benefit profile for prophylaxis in appropriately selected patients, assuaging clinician concerns about causing undue harm.

The overwhelming evidence from these trials had a profound impact on clinical practice. The data were used to help develop and validate risk assessment models designed to identify medical patients at high risk for VTE who would benefit most from prophylaxis. Most importantly, this body of research formed the evidentiary backbone for major international clinical practice guidelines. Influential guidelines, such as those from the American College of Chest Physicians, were updated to issue strong recommendations for the routine use of pharmacological thromboprophylaxis with agents like LMWH or fondaparinux in acutely ill hospitalized medical patients with risk factors for VTE, unless contraindicated (Geerts et al., 2008).

CONCLUSION

The pivotal literature examining pharmacological thromboprophylaxis in acutely ill medical patients provides a clear and definitive conclusion. A series of large, well-conducted, randomized controlled trials consistently demonstrated that prophylactic doses of anticoagulants, such as low-molecular-weight heparins and fondaparinux, significantly reduce the incidence of venous thromboembolism.

This substantial benefit was achieved with an acceptable safety profile, establishing a clear net clinical benefit for at-risk patients. This research effectively ended decades of clinical uncertainty and transformed the standard of care, elevating VTE prevention to a fundamental priority in the management of hospitalized medical patients. The implementation of these findings into routine clinical practice has been instrumental in improving patient safety and preventing countless instances of VTE-related morbidity and mortality.

REFERENCES

- Alikhan, R., Cohen, A.T., Combe, S., Samama, M.M., Desjardins, L., Eldor, A. and Janbon, C. (2003) 'Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study', *Archives of Internal Medicine*, 163(17), pp. 2015-2016.
- Cohen, A.T., Davidson, B.L., Gallus, A.S., Lassen, M.R., Prins, M.H., Tomkowski, W., Turpie, A.G. and Egberts, J. (2006) 'Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial', *BMJ*, 332(7537), pp. 325-329.
- Geerts, W.H., Bergqvist, D., Pineo, G.F., Heit, J.A., Samama, C.M., Lassen, M.R. and Colwell, C.W. (2008) 'Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)', *Chest*, 133(6 Suppl), pp. 381S-453S.
- Leizorovicz, A., Cohen, A.T., Turpie, A.G., Olsson, C.G., Vaitkus, P.T. and Goldhaber, S.Z. (2004) 'Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients', *Circulation*, 110(7), pp. 874-879.